


### REMARKS

Claims 1-33 having been cancelled and claims 34-44 having been added, the Applicant respectfully submits that 11 claims, specifically claims 34-44, are properly under consideration in this application, with claims 34 and 39 being independent claims. Consideration and prompt action on these claims is respectfully requested.

Claims 34-38 are directed to the use of a compound having Formula I



to prepare a pharmaceutical composition for treating a subject susceptible to infection by an infectious agent. Claims 39-44 are directed to methods of treating a subject susceptible to infection by an infectious agent in which administering a therapeutically effective amount of a compound, a tautomer of the compound or a pharmaceutically acceptable salt of the compound, according to Formula I to such an individual. The Applicant respectfully submits that support for these claims is found in the Specification at, *inter alia*, pages 1-5 and 12-16, and original claims 1-11, particularly with regard to the prophylactic use of the disclosed compositions.

**CONCLUSION**


Accordingly, in view of the above amendments and remarks, an early indication of the allowability of each of claims 34-44 in connection with the present application is earnestly solicited.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Timothy R. Wyckoff at the telephone number of the undersigned below.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 08-0750 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

HARNESS, DICKEY & PIERCE, P.L.C

By:   
Gregory P. Brummett  
Reg. No. 41,646

P.O. Box 8910  
Reston, Virginia 20195  
(703) 668-8000  
TRW:GPB:mh